Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug;48(8):300060520946872.
doi: 10.1177/0300060520946872.

Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis

Wang Gu  1 , Zhong Tong  1
Affiliations
Meta-Analysis

Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis

Wang Gu et al. J Int Med Res. 2020 Aug.

Abstract

Objective: Microvascular invasion is shown to be an independent risk factor for liver cancer recurrence. Timely treatment may reduce the recurrence rate and prolong total survival time. The aim of this study was to investigate the effectiveness of sorafenib in treating patients with hepatocellular carcinoma (HCC) and microvascular invasion.

Methods: A comprehensive literature search was conducted in PubMed, EMBASE, MEDLINE, web of science and Cochrane Library databases for articles published up to December 2019. Two researchers independently reviewed and cross-checked independent reports with sufficient information. A meta-analysis was conducted to assess the impact of sorafenib on mortality in patients with HCC and microvascular involvement.

Results: Four studies were included in the qualitative and quantitative analyses, comprising 955 cancer events and 505 cancer deaths. Meta-analyses showed that sorafenib treatment was associated with an improved survival rate versus no sorafenib treatment in patients with HCC and microvascular invasion (relative risk 1.369, 95% confidence interval 1.193, 1.570).

Conclusions: Sorafenib treatment may improve survival in patients with HCC and microvascular invasion. However, due to the potential for residual confounding, the results should be interpreted with caution.

Keywords: Sorafenib; hepatocellular carcinoma (HCC); microvascular invasion (MVI).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of article selection.
Figure 2.
Figure 2.
Forest plot of the relationship between the use of sorafenib and outcome of treatment in patients with hepatocellular carcinoma with microvascular invasion.
Figure 3.
Figure 3.
Begg’s funnel plot showing no publication bias in the four included studies.
Figure 4.
Figure 4.
Sensitivity analysis of the four included studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128. - PMC - PubMed
    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917. - PubMed
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917. - PubMed
    1. Onoe T, Yamaguchi M, Irei T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc Epub ahead of print 18 December 2019. DOI: 10.1007/s00464-019-07246-3. - PubMed
    1. Ou DP, Yang LY, Huang GW, et al. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol 2005; 11: 2061–2066. - PMC - PubMed

MeSH terms

  NODES
COMMUNITY 1
twitter 2